First Trust Advisors LP Bei Gene, Ltd. Transaction History
First Trust Advisors LP
- $101 Billion
- Q3 2024
A detailed history of First Trust Advisors LP transactions in Bei Gene, Ltd. stock. As of the latest transaction made, First Trust Advisors LP holds 247,632 shares of BGNE stock, worth $46.5 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
247,632
Previous 250,351
1.09%
Holding current value
$46.5 Million
Previous $35.7 Million
55.65%
% of portfolio
0.06%
Previous 0.04%
Shares
25 transactions
Others Institutions Holding BGNE
# of Institutions
249Shares Held
45.3MCall Options Held
292KPut Options Held
119K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.98 Billion25.41% of portfolio
-
Capital International Investors Los Angeles, CA6.43MShares$1.21 Billion0.29% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$972 Million26.65% of portfolio
-
Primecap Management CO Pasadena, CA4.97MShares$934 Million0.84% of portfolio
-
Baillie Gifford & CO3.71MShares$696 Million0.64% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $19.5B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...